Sanofi Collaboration Drives Lexicon Pharma's (LXRX) 4Q Success; Wedbush Raises Price Target to $28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Lexicon Pharma (LXRX) Reports Q4 EPS of $0.76
March 1, 2016 7:11 AM ESTLexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.76, versus ($0.03) reported last year. Revenue for the quarter came in at $127.3 million, versus $21.5 million reported last year.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... MoreTrading Radar for 3/1: AutoZone (AZO), Dollar Tree (DLTR), Donaldson (DCI), TiVo (TIVO), Veeva (VEEV) Report
February 29, 2016 2:16 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
Ares Commercial Real Estate (NYSE: ACRE) - consensus EPS $0.27
AutoZone (NYSE: AZO) - consensus EPS $7.28
Bank of Nova Scotia (NYSE: BNS) - consensus EPS $1.42
Concert Pharma (Nasdaq: CNCE) - consensus loss $0.05
Del Frisco's (Nasdaq: DFRG) - consensus EPS $0.36
Diana... More
